Ethical review of off-label drugs during the COVID-19 pandemic  

作　　者：Qiu-Yu Li Ye Lv Zhuo-Yu An Ni-Ni Dai Xue Hong Yu Zhang Li-Jun Liang 

机构地区：[1]Department of Pulmonary and Critical Care Medicine,Peking University Third Hospital,Beijing 100191,China [2]Advanced Institute for Medical Sciences,Dalian Medical University,Dalian 116044,Liaoning Province,China [3]Peking University Institute of Hematology,Peking University People’s Hospital,Beijing 100191,China [4]Department of Ethics Office,Peking University Third Hospital,Beijing 100191,China

出　　处：《World Journal of Clinical Cases》2022年第17期5541-5550,共10页世界临床病例杂志

基　　金：Supported by National Natural Science Foundation of China,No.81900641;Peking University Health Center for Combating the Pandemic Programs,No.BMU 2021MX020,and No.BMU 2022MX008.

摘　　要：High-quality scientific research is very important in attempting to effectively control the coronavirus disease 2019(COVID-19)pandemic and ensure people’s health and safety.Chloroquine(CQ)and hydroxychloroquine(HCQ)have received much attention.This article comprehensively investigates the ethical review of off-label CQ and HCQ research during the COVID-19 pandemic with regard to strictly abiding by review standards,improving review efficiency,ensuring the rights and interests of subjects and that ethics committees conduct independent reviews,and achieving full ethics supervision of research conducted during an emergency.Research must be both rigorous and prudent to ensure the best outcome,with the maximization of benefits as the core principle.Standardization of the application,implementation and ethical review processes are needed to prevent unnecessary risk.

关 键 词：COVID-19 OFF-LABEL CHLOROQUINE HYDROXYCHLOROQUINE 

分 类 号：R95[医药卫生—药学] R-052